Loading…
Reported covered position: COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA / Sr. LA Rep. Baron Hill
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MLK COMMUNITY HEALTHCARE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to federal regulations and legislation that could impact non-profit health care providers generally, or MLK Community Healthcare specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| EDWARDS LIFESCIENCES LLC |
| 22 |
| 2021–2026 |
| MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 22 | 2021–2026 |
| AKEBIA THERAPEUTICS, INC. | 21 | 2021–2026 |
| AMGEN, INC. | 21 | 2021–2026 |
| BAYER CORPORATION | 21 | 2021–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 21 | 2021–2026 |
| CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. | 21 | 2021–2026 |
| FINDHELP | 21 | 2021–2026 |
| GLAXOSMITHKLINE, INC. | 21 | 2021–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 21 | 2021–2026 |
| PTC THERAPEUTICS | 21 | 2021–2026 |
| STRYKER CORPORATION | 21 | 2021–2026 |
| CENTENE CORPORATION | 20 | 2021–2026 |
| ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) | 20 | 2021–2026 |
| POLARIS INDUSTRIES | 19 | 2022–2026 |
| GRUBHUB HOLDINGS INC. | 17 | 2022–2026 |
| MOTION PICTURE ASSOCIATION | 17 | 2021–2025 |
| NOVARTIS | 17 | 2023–2026 |
| BIOMARIN PHARMACEUTICAL INC. | 16 | 2023–2026 |
| NATIONAL LIFELINE ASSOCIATION | 15 | 2021–2025 |
| QUALTRICS LLC | 15 | 2023–2026 |
| THE ASSISTANCE FUND | 15 | 2021–2024 |
| MARQUIS MANAGEMENT | 14 | 2023–2026 |
| RIGETTI & CO, LLC | 14 | 2023–2026 |
| CASA SYSTEMS, INC. | 13 | 2021–2024 |
| ALG SENIOR LLC | 12 | 2021–2024 |
| HCBS ADVOCACY, LLC | 12 | 2022–2024 |
| TARGET ALS FOUNDATION INC. | 12 | 2022–2024 |
| VALERO SERVICES, INC. | 12 | 2023–2026 |
| YORK SPACE SYSTEMS | 12 | 2023–2025 |
| BLACKSEA TECHNOLOGIES | 10 | 2023–2025 |
| FUSE ENERGY TECHNOLOGIES CORP. | 10 | 2024–2026 |
| MATRIX MEDICAL NETWORK | 10 | 2021–2023 |
| NYU LANGONE HEALTH | 10 | 2024–2026 |
| E.J. SAAD LAW FIRM | 9 | 2024–2025 |
| ECS | 9 | 2024–2026 |
| GREATER ORLANDO AVIATION AUTHORITY | 9 | 2023–2024 |
| HORIZON PHARMA | 9 | 2021–2023 |
| QUOTE VELOCITY | 9 | 2024–2025 |
| ADARGA | 8 | 2023–2024 |
| LOCKTON MANAGEMENT, LLC | 8 | 2021–2023 |
| OROS | 8 | 2022–2023 |
| SCP-HEALTH | 8 | 2021–2023 |
| THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 8 | 2025–2026 |
| BIOMERIEUX, INC. | 7 | 2024–2025 |
| EPIGENOMICS INC. | 7 | 2021–2022 |
| METHODIST CHILDREN'S HOME SOCIETY FAMILY OF SERVICES | 7 | 2025–2026 |
| NATIONAL RESILIENCE, INC. | 7 | 2023–2024 |
| OREGON INLET FISHING CENTER | 7 | 2023–2024 |
| RECESS | 7 | 2021–2023 |
| SAS INSTITUTE, INC. | 7 | 2021–2023 |
| SIEMENS HEALTHINEERS | 7 | 2021–2023 |
| ASSOCIATION OF DENTAL SUPPORT ORGANIZATIONS | 6 | 2021–2022 |
| COLORECTAL CANCER ALLIANCE | 6 | 2025–2026 |
| CUISINE SOLUTIONS, INC. | 6 | 2024–2025 |
| EMOVIS TECHNOLOGIES US, INC. | 6 | 2023–2024 |
| HEARTLAND FOOD PRODUCTS GROUP | 6 | 2025–2026 |
| TRANSMEDICS | 6 | 2025–2026 |
| UIPATH | 6 | 2024–2025 |
| DEVOLLI CORPORATION | 5 | 2024–2025 |
| IMPOSSIBLE FOODS INC. | 5 | 2021–2022 |
| THE TRANSPORT PROJECT | 5 | 2024–2025 |
| ADVANCED DIAGNOSTICS HEALTHCARE SYSTEM | 4 | 2024 |
| DIGNITY AND WELLNESS PATIENT SOLUTIONS, LLC | 4 | 2025 |
| NEKTAR THERAPEUTICS | 4 | 2021–2022 |
| REPUBLIC OF INDIA | 4 | 2025–2026 |
| UNDIAGNOSED DISEASE NETWORK FOUNDATION | 4 | 2024–2025 |
| Zogenix, Inc. | 4 | 2021–2022 |
| CARLSMED, INC. | 3 | 2024 |
| DECISION LENS INC | 3 | 2025 |
| WK KELLOGG CO (FKA KELLOGG COMPANY) | 3 | 2023 |
| CDR MAGUIRE | 2 | 2022 |
| CNX RESOURCES CORPORATION | 2 | 2024 |
| DHL EXPRESS (USA), INC. | 2 | 2022 |
| MONTANA HEALTH SOLUTIONS, INC. | 2 | 2026 |
| NEPHROLOGY ASSOCIATES OF NORTHERN ILLINOIS AND INDIANA | 2 | 2021 |
| ULSE INC. D/B/A UL STANDARDS & ENGAGEMENT | 2 | 2026 |
| CARDINAL HEALTH | 1 | 2026 |
| NASSAU HEALTH SYSTEM CORP. | 1 | 2025 |
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. · Firm: BGR GOVERNMENT AFFAIRS
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ECS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to DOD artificial intelligence technology in the NDAA and defense appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ULSE INC. D/B/A UL STANDARDS & ENGAGEMENT via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to lithium-ion batteries and consumer safety standards
Filing targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, SENATE
FUSE ENERGY TECHNOLOGIES CORP. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Filing targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
POLARIS INDUSTRIES via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on tax credits for non-road vehicles; Federal land access for recreational off-highway vehicles
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, U.S. Trade Representative (USTR), White House Office
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on trade related matters and enhancing vision health; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Provide strategic counsel and advocate on issues related to health, tax and trade policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MARQUIS MANAGEMENT via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
RIGETTI & CO., LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to quantum computing, appropriations and NDAA
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
VALERO SERVICES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
QUALTRICS LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GRUBHUB HOLDINGS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues related to food insecurity, privacy and workforce
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MONTANA HEALTH SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to home and community-based services
Provide strategic counsel and advocate on issues related to home and community-based services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
COLORECTAL CANCER ALLIANCE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to colorectal cancer research and funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
THE CHILDREN'S HOSPITAL OF PHILADELPHIA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and The Children's Hospital of Philadelphia specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GRUBHUB HOLDINGS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues related to food insecurity, privacy and workforce
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
MLK COMMUNITY HEALTHCARE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to federal regulations and legislation that could impact non-profit health care providers generally, or MLK Community Healthcare specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
POLARIS INDUSTRIES via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on tax credits for non-road vehicles; Federal land access for recreational off-highway vehicles
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, U.S. Trade Representative (USTR), White House Office
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on trade related matters and enhancing vision health; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MONTANA HEALTH SOLUTIONS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to home and community-based services
Provide strategic counsel and advocate on issues related to home and community-based services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ECS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to DOD artificial intelligence technology in the NDAA and defense appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
COLORECTAL CANCER ALLIANCE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to colorectal cancer research and funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ULSE INC. D/B/A UL STANDARDS & ENGAGEMENT via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to lithium-ion batteries and consumer safety standards
Filing targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, SENATE
FUSE ENERGY TECHNOLOGIES CORP. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Health care reform and regulatory implementation and funding, Medicaid, Graduate Medical Education; CHIP Reauthorization; DSH Payments; FY'25 federal appropriations; mental health reform; H.R. 1 One Big Beautiful Bill Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
MARQUIS MANAGEMENT via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
RIGETTI & CO., LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to quantum computing, appropriations and NDAA
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
VALERO SERVICES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
QUALTRICS LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
METHODIST CHILDREN'S HOME SOCIETY FAMILY OF SERVICES via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRYKER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the medical device industry generally, and Stryker Corporation specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals and health plans generally and Mass General Brigham specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MLK COMMUNITY HEALTHCARE via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide guidance and advocacy with regard to federal regulations and legislation that could impact non-profit health care providers generally, or MLK Community Healthcare specifically.
Filing targets: SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FINDHELP via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on federal health policy related to social care programs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office
POLARIS INDUSTRIES via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on tax credits for non-road vehicles; Federal land access for recreational off-highway vehicles
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, U.S. Trade Representative (USTR), White House Office
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic guidance and counsel on trade related matters and enhancing vision health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRANSMEDICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy regarding utilization of donor organs for transplantation
COLORECTAL CANCER ALLIANCE via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to colorectal cancer research and funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ECS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to DOD artificial intelligence technology in the NDAA and defense appropriations.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
"Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FUSE ENERGY TECHNOLOGIES CORP. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Provide strategic counsel and advocate on issues related to fusion energy technology and military applications of fusion technology including NDAA authorizations and appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEARTLAND FOOD PRODUCTS GROUP via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Provide strategic counsel and advocate on issues related to U.S. based sweetener production
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
MARQUIS MANAGEMENT via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
RIGETTI & CO., LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to quantum computing, appropriations and NDAA
Filing targets: Commerce, Dept of (DOC), Energy, Dept of, HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
VALERO SERVICES, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Provide strategic counsel and advocacy on issues relating to transportation fuels policy, corporate taxation, biofuels and sustainable aviation fuels.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
QUALTRICS LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Provide strategic counsel and advocacy on issues relating to data analytics, defense matters and appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Provide strategic counsel and advocacy on issues relating to energy, tax, foreign ethanol markets and aviation fuel policies
Filing targets: Agriculture, Dept of (USDA), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office